CANVAC

In this project, the use of nanocarriers produced by the company Virometix will be investigated as potential antigen carriers, aiming at the development of cancer vaccines. The main body of work will involve in vitro dendritic cell systems cultured in the presence of different nanoparticles, as well as co-cultures with CD4⁺ and CD8⁺ T lymphocytes, in order to examine potential activation due to antigen presentation. At the conclusion of the carrier evaluation, if positive results are obtained, the functionality of these carriers may be studied in vivo using cancer models.